Liraglutide: difference between revisions
Diff·revision 11 → 12·15:04, 18 Dec 2024
Difference between revision 11 and revision 12 of Liraglutide. 10 lines changed; the page grew by 898 bytes.
| Revision 11 — 06:21, 1 Dec 2024 MolarMassMaeve (talk) move the trade-name history out of the lead and into §Regulatory history 3,273 bytes ±0 | Revision 12 — 15:04, 18 Dec 2024 MazdutideMads (talk) fix hyphenation per PP:MOS 4,171 bytes +898 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Liraglutide | 2 | | name = Liraglutide |
| + | 3 | | subtitle = Clinical data | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | INN = liraglutide | 5 | | INN = liraglutide |
| ⋮ | ⋮ | ||
| 10 | | Molar mass = 3,751.20 g·mol⁻¹ | 11 | | Molar mass = 3,751.20 g·mol⁻¹ |
| 11 | | Residues = 31 | 12 | | Residues = 31 |
| + | 13 | <!-- Pharmacokinetics --> | |
| + | 14 | | Half-life = ≈13 h | |
| + | 15 | | Bioavailability, SC = ≈55% | |
| + | 16 | | Albumin binding = >98% | |
| 12 | }} | 17 | }} |
| 13 | 18 | ||
| ⋮ | ⋮ | ||
| 24 | 29 | ||
| 25 | The comparison with [[Semaglutide|semaglutide]] is instructive: substituting the C-16 monoacid for a C-18 diacid, lengthening the spacer with two OEG units, and adding Aib at position 8 together take the half-life from about thirteen hours to about 165 hours. | 30 | The comparison with [[Semaglutide|semaglutide]] is instructive: substituting the C-16 monoacid for a C-18 diacid, lengthening the spacer with two OEG units, and adding Aib at position 8 together take the half-life from about thirteen hours to about 165 hours. |
| + | 31 | ||
| + | 32 | == Clinical evidence == | |
| + | 33 | In type 2 diabetes, liraglutide 1.8 mg daily reduces glycated haemoglobin by roughly 1.1–1.5 percentage points. At 3.0 mg daily for weight management, mean weight loss in the pivotal trial was about 8% against about 2.6% for placebo at 56 weeks — substantially less than the weekly agents that followed.{{r|marso2016}} | |
| + | 34 | ||
| + | 35 | The [[LEADER trial|LEADER]] trial randomised 9,340 people with type 2 diabetes and high cardiovascular risk and reported a hazard ratio of 0.87 (95% CI 0.78–0.97) for the primary composite cardiovascular outcome, with a reduction in cardiovascular death. It was among the first trials to establish that an incretin therapy could reduce cardiovascular events rather than merely not increase them.{{r|marso2016}} | |
| 26 | 36 | ||
| 27 | == References == | 37 | == References == |